

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. - 5. (Cancelled)

6. (Currently Amended) A method of treating a patient diagnosed with fibromyalgia treatment comprising administering to [a] the patient diagnosed with fibromyalgia about 15 to about 360 mg AAT alpha-1-antitrypsin per kg patient body mass, and repeating the administration at least once with a periodicity of between 3 and 31 days.

7. (Currently Amended) ~~Method, according to~~ The method of Claim 6, wherein AAT alpha-1-antitrypsin is administered at a dose of between 25 and 60 mg/kg every per week ~~or multiples of these quantities adjusted according to the time interval foreseen until the next dose, in a proportional manner.~~

8. (Currently Amended) A method of treatment comprising administering sufficient AAT alpha-1-antitrypsin to a patient diagnosed with fibromyalgia as will increase the patient's AAT alpha-1-antitrypsin level by about 100% over basal level at about 7 days following administration and repeating the administration at least once at about 3 to 31 days.

9. (Currently Amended) ~~Method, according to~~ The method of Claim 8, wherein the administration of AAT alpha-1-antitrypsin is repeated at least once at about 7 to 21 days.

10. (Currently Amended) A method of ~~treatment~~ treating a patient diagnosed with fibromyalgia comprising administering to [a] the patient diagnosed with fibromyalgia a quantity of AAT alpha-1-antitrypsin as will increase serum AAT alpha-1-antitrypsin levels to about 5-fold greater than basal levels at 24 hours following administration.

11. (Currently Amended) ~~Method, according to~~ The method of Claim 10, wherein the administration is repeated one or more times at about 3 to 31 days.

12. (Currently Amended) ~~Method, according to~~ The method of Claim 10, wherein the administration is repeated one or more times at about 7 to 21 days.

13. (Currently Amended) ~~Method, according to~~ The method of Claim 10, wherein a quantity of AAT alpha-1-antitrypsin is administered as will increase serum AAT alpha-1-antitrypsin levels about 8-fold over basal levels at 24 hours following administration, and the administration is repeated one or more times at about 7 to 21 days.

14. (Currently Amended) A method of treating a patient diagnosed with fibromyalgia comprising administering to said patient by parenteral infusion about 15

to 360 mg AAT alpha-1-antitrypsin per kg patient body mass, and repeating said infusion at least once at 3 to 31 days to effect a diminishment of the symptoms of fibromyalgia in said patient.

15. (Currently Amended) ~~Method, according to~~ The method of Claim 14, wherein the dose of AAT alpha-1-antitrypsin is between 25 and 60 mg AAT alpha-1-antitrypsin /kg body mass, and the infusion is repeated at least once at about 7 to 21 days.

16. (Currently Amended) ~~Method, according to~~ The method of Claim 14 [or 15], wherein the administration is carried out by intravenous infusion.

16. (Currently Amended) ~~Method, according to~~ The method of Claim 14 [or 15], wherein the administration is carried out by intravenous infusion and the dose of alpha-1-antitrypsin is between 25 and 60 mg alpha-1-antitrypsin/kg body mass, and the infusion is repeated at least once at about 7 to 21 days.